** Shares of Cibus CBUS.O down 30.5% premarket to $1.64 after agricultural biotechnology firm's follow-on prices
** CBUS shares set for fifth straight session of declines
** San Diego, California-based gene-editing co announces ~15.7 mln shares at $1.75 for $27.5 mln gross proceeds
** Offering price represents 25.8% discount to stock's last close
** Board chairman and co-founder Rory Riggs bought ~5.7 mln shares, or $10 mln worth of the offering
** Co says intends to use net offering proceeds to fund development of weed management productivity traits in rice and for working capital and other general purposes, as it pursues longer-term financing
** With ~34.4 mln shares outstanding, co has $81 mln market cap
** CBUS shares hit a record intraday low of $1.40 on Apr 7. Stock ended 2024 at $2.78 and was trading around $11 a year ago
** 3 of 4 analysts covering CBUS rate stock "buy" and 1 rates "hold"; PTs range from as low as $2 (Jefferies) to as high as $25 (H.C. Wainwright), latest LSEG data shows
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。